Geovax Labs Risk Profile Appears Stable, But Investors Should Watch for Emerging SEC-Disclosed Pressures
GeoVax Labs, Inc. 2026: Revenue $0 EPS ($0.97) — 10-Q Summary
GeoVax Q2 FY26 net loss narrows to $4.43 million, or $0.97 a share; revenue posts no revenue
GeoVax gets Nasdaq notice for failing $2.5 million stockholders’ equity requirement
GeoVax Labs shareholders approve Wipfli as independent auditor for 2026
12 Health Care Stocks Moving In Monday's Pre-Market Session